Glycosylation is a novel TGF?1-independent post-translational modification of Smad2
View/ Open
Publisher version (Check access options)
Check access options
Date
2019Author
Gotoh, TakayaIwahana, Hiroyuki
Kannan, Surya
Marei, Reham Ghazal
Mousa, Hanaa
Elgamal, Mahmoud
Souchelnytskyi, Serhiy
...show more authors ...show less authors
Metadata
Show full item recordAbstract
Smad2 is a crucial component of intracellular signaling by transforming growth factor-? (TGF?). Here we describe that Smad2 is glycosylated, which is a novel for Smad2 post-translational modification. We showed that the Smad2 glycosylation was inhibited upon treatment of cells with 17?-estradiol, and was enhanced in cells in a dense culture as compared to cells in a sparse culture. The Smad2 glycosylation was not dependent on the C-terminal phosphorylation of Smad2, and was not affected by TGF?1 treatment of the cells. Smad2 was glycosylated at multiple sites, and one of the predicted sites is Serine110. Thus, Smad2 is glycosylated, and this post-translational modification was modulated by 17?-estradiol but not by TGF?1. - 2019 Elsevier Inc.
Collections
- Medicine Research [1518 items ]